{"id":"experimental-rosuvastatin-ezetimibe-10","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal disturbance"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosuvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, thereby lowering LDL cholesterol production. Ezetimibe selectively inhibits the Niemann-Pick C1-like 1 (NPC1L1) transporter in the intestinal brush border, reducing dietary and biliary cholesterol absorption. Together, these complementary mechanisms produce additive LDL-lowering effects.","oneSentence":"This combination reduces LDL cholesterol by inhibiting HMG-CoA reductase (rosuvastatin) and blocking intestinal cholesterol absorption (ezetimibe).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:39:31.972Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction"}]},"trialDetails":[{"nctId":"NCT05661552","phase":"PHASE4","title":"Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2022-12-01","conditions":"Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia","enrollment":108},{"nctId":"NCT03993236","phase":"PHASE4","title":"Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke","status":"COMPLETED","sponsor":"Keun-Sik Hong","startDate":"2019-09-09","conditions":"Stroke, Ischemic","enrollment":584},{"nctId":"NCT04968509","phase":"PHASE3","title":"Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2024-03-22","conditions":"Aortic Stenosis","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rosuzet tab 10/10 mg"],"phase":"marketed","status":"active","brandName":"Experimental: Rosuvastatin/Ezetimibe 10","genericName":"Experimental: Rosuvastatin/Ezetimibe 10","companyName":"Keun-Sik Hong","companyId":"keun-sik-hong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces LDL cholesterol by inhibiting HMG-CoA reductase (rosuvastatin) and blocking intestinal cholesterol absorption (ezetimibe). Used for Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}